An integrated multiplexed electrochemical platform for the selective detection of viral protein and RNA to differentiate active HIV-1 infection from vaccine induced seropositivity

NIH RePORTER · NIH · N43 · $300,000 · view on reporter.nih.gov ↗

Abstract

Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity: Several years of clinical trials have revealed that some HIV vaccines can elicit long-lasting (>15 years) serological immune responses that can be confused with HIV infection in common diagnostic tests. This phenomenon is known as vaccine-induced sero-reactivity or sero-positivity (VISR/VISP). The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to VISP, with high sensitivity and specificity.

Key facts

NIH application ID
10667352
Project number
75N93022C00031-0-9999-1
Recipient
VITRUVIAN BIO, LLC
Principal Investigator
DAVID SKRODZKI
Activity code
N43
Funding institute
NIH
Fiscal year
2022
Award amount
$300,000
Award type
Project period
2022-07-01 → 2023-06-30